From The Economic Times · Reuters · · 1m
TL;DR: US stocks drop as FDA rejects lung cancer drug approval
Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab.
US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%. Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab. US Food and Drug Administration declined to approve Summit Therapeutics' experimental lung cancer drug ivonescimab. Summit Therapeutics shares fell 14% at $12.16 in morning trading after FDA decision.
- FDA rejects lung cancer drug
- Shares drop 14%
- Drug study results
- Regional patient outcomes
Read the story version — the same reporting as a swipeable deck of 7 cards.
